Study on the correlation between chronic diseases patients'perceived drug benefits and their health-related quality of life under the centralized drug procurement policy
10.3969/j.issn.1674-2982.2024.12.006
- VernacularTitle:药品集中采购政策下慢性病患者药品福利感知与健康相关生命质量的相关性研究
- Author:
Jing-yu XU
1
;
Shao-liang TANG
1
;
Hui-lin JIAO
1
;
Xiao-yan MAO
1
Author Information
1. 南京中医药大学卫生经济管理学院 江苏南京 210023
- Publication Type:Journal Article
- Keywords:
Centralized drug procurement;
Drug benefit;
Chronic disease patients;
Health-related quality of life
- From:
Chinese Journal of Health Policy
2024;17(12):37-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the correlation between perceived drug benefits and health-related quality of life of chronical disease patients under the centralized drug procurement policy.Methods:A multistage stratified random sampling method was used to select 1026 patients with chronic diseases in five provinces,namely,Jiangsu,Guangdong,Heilongjiang,Gansu,and Ningxia Hui Autonomous Region,and to analyze the current level of perceived drug benefits and health-related quality of life of 924 patients after centralized drug purchasing.Based on the linear regression model,the correlation between perceived drug benefits and health-related quality of life of patients with chronic diseases under the policy of centralized drug procurement was explored,and the heterogeneity among different populations was explored by grouping them according to the place of residence and the number of chronic diseases.Results:There were significant correlations between the perceived affordability and accessibility of medicines and health-related quality of life of patients with chronic diseases under the centralized drug procurement policy ( P<0.01 ) Recommendations:In order to improve the effect of the centralized drug procurement policy and to further increase the welfare of medicines for patients with chronic diseases,the government should continuously expand the coverage of selected drug categories,strengthen the management of distribution and supply chains for selected drugs,and focus on promoting the fairness of policy implementation.
